Cargando…

Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease

BACKGROUND: Estimating cardiovascular (CV) event accrual is important for outcome trial planning. Limited data exist describing event accrual patterns in patients with type 2 diabetes (T2D). We compared apparent CV event accrual patterns with true event rates in the Trial Evaluating Cardiovascular O...

Descripción completa

Detalles Bibliográficos
Autores principales: Bethel, M. Angelyn, Sourij, Harald, Stevens, Susanna R., Hannan, Karen, Lokhnygina, Yuliya, Adler, Amanda I., Peterson, Eric D., Holman, Rury R., Lopes, Renato D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054031/
https://www.ncbi.nlm.nih.gov/pubmed/36978066
http://dx.doi.org/10.1186/s12933-023-01802-x
_version_ 1785015555350069248
author Bethel, M. Angelyn
Sourij, Harald
Stevens, Susanna R.
Hannan, Karen
Lokhnygina, Yuliya
Adler, Amanda I.
Peterson, Eric D.
Holman, Rury R.
Lopes, Renato D.
author_facet Bethel, M. Angelyn
Sourij, Harald
Stevens, Susanna R.
Hannan, Karen
Lokhnygina, Yuliya
Adler, Amanda I.
Peterson, Eric D.
Holman, Rury R.
Lopes, Renato D.
author_sort Bethel, M. Angelyn
collection PubMed
description BACKGROUND: Estimating cardiovascular (CV) event accrual is important for outcome trial planning. Limited data exist describing event accrual patterns in patients with type 2 diabetes (T2D). We compared apparent CV event accrual patterns with true event rates in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). METHODS: Centrally adjudicated event dates and accrual rates for a 4-point major adverse CV event composite (MACE-4; includes CV death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina hospitalization), MACE-4 components, all-cause mortality (ACM), and heart failure hospitalization were compiled. We used three graphical methods (Weibull probability plot, plot of negative log of the Kaplan–Meier survival distribution estimate, and the Epanechnikov kernel-smoothed estimate of the hazard rate) to examine hazard rate morphology over time for the 7 outcomes. RESULTS: Plots for all outcomes showed real-time constant event hazard rates for the duration of the follow-up, confirmed by Weibull shape parameters. The Weibull shape parameters for ACM (1.14, 95% CI 1.08–1.21) and CV death (1.08, 95% CI 1.01–1.16) were not sufficiently > 1 as to require non-constant hazard rate models to accurately depict the data. The time lag between event occurrence and event adjudication being completed, the adjudication gap, improved over the course of the trial. CONCLUSIONS: In TECOS, the nonfatal event hazard rates were constant over time. Small increases over time in the hazard rate for fatal events would not require complex modelling to predict event accrual, providing confidence in traditional modelling methods for predicting CV outcome trial event rates in this population. The adjudication gap provides a useful metric to monitor within-trial event accrual patterns. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov NCT00790205. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-023-01802-x.
format Online
Article
Text
id pubmed-10054031
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100540312023-03-30 Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease Bethel, M. Angelyn Sourij, Harald Stevens, Susanna R. Hannan, Karen Lokhnygina, Yuliya Adler, Amanda I. Peterson, Eric D. Holman, Rury R. Lopes, Renato D. Cardiovasc Diabetol Research BACKGROUND: Estimating cardiovascular (CV) event accrual is important for outcome trial planning. Limited data exist describing event accrual patterns in patients with type 2 diabetes (T2D). We compared apparent CV event accrual patterns with true event rates in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). METHODS: Centrally adjudicated event dates and accrual rates for a 4-point major adverse CV event composite (MACE-4; includes CV death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina hospitalization), MACE-4 components, all-cause mortality (ACM), and heart failure hospitalization were compiled. We used three graphical methods (Weibull probability plot, plot of negative log of the Kaplan–Meier survival distribution estimate, and the Epanechnikov kernel-smoothed estimate of the hazard rate) to examine hazard rate morphology over time for the 7 outcomes. RESULTS: Plots for all outcomes showed real-time constant event hazard rates for the duration of the follow-up, confirmed by Weibull shape parameters. The Weibull shape parameters for ACM (1.14, 95% CI 1.08–1.21) and CV death (1.08, 95% CI 1.01–1.16) were not sufficiently > 1 as to require non-constant hazard rate models to accurately depict the data. The time lag between event occurrence and event adjudication being completed, the adjudication gap, improved over the course of the trial. CONCLUSIONS: In TECOS, the nonfatal event hazard rates were constant over time. Small increases over time in the hazard rate for fatal events would not require complex modelling to predict event accrual, providing confidence in traditional modelling methods for predicting CV outcome trial event rates in this population. The adjudication gap provides a useful metric to monitor within-trial event accrual patterns. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov NCT00790205. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-023-01802-x. BioMed Central 2023-03-28 /pmc/articles/PMC10054031/ /pubmed/36978066 http://dx.doi.org/10.1186/s12933-023-01802-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bethel, M. Angelyn
Sourij, Harald
Stevens, Susanna R.
Hannan, Karen
Lokhnygina, Yuliya
Adler, Amanda I.
Peterson, Eric D.
Holman, Rury R.
Lopes, Renato D.
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
title Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
title_full Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
title_fullStr Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
title_full_unstemmed Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
title_short Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
title_sort time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054031/
https://www.ncbi.nlm.nih.gov/pubmed/36978066
http://dx.doi.org/10.1186/s12933-023-01802-x
work_keys_str_mv AT bethelmangelyn timedependenteventaccumulationinacardiovascularoutcometrialofpatientswithtype2diabetesandestablishedatheroscleroticcardiovasculardisease
AT sourijharald timedependenteventaccumulationinacardiovascularoutcometrialofpatientswithtype2diabetesandestablishedatheroscleroticcardiovasculardisease
AT stevenssusannar timedependenteventaccumulationinacardiovascularoutcometrialofpatientswithtype2diabetesandestablishedatheroscleroticcardiovasculardisease
AT hannankaren timedependenteventaccumulationinacardiovascularoutcometrialofpatientswithtype2diabetesandestablishedatheroscleroticcardiovasculardisease
AT lokhnyginayuliya timedependenteventaccumulationinacardiovascularoutcometrialofpatientswithtype2diabetesandestablishedatheroscleroticcardiovasculardisease
AT adleramandai timedependenteventaccumulationinacardiovascularoutcometrialofpatientswithtype2diabetesandestablishedatheroscleroticcardiovasculardisease
AT petersonericd timedependenteventaccumulationinacardiovascularoutcometrialofpatientswithtype2diabetesandestablishedatheroscleroticcardiovasculardisease
AT holmanruryr timedependenteventaccumulationinacardiovascularoutcometrialofpatientswithtype2diabetesandestablishedatheroscleroticcardiovasculardisease
AT lopesrenatod timedependenteventaccumulationinacardiovascularoutcometrialofpatientswithtype2diabetesandestablishedatheroscleroticcardiovasculardisease